Tag Archives: Trevena

February, 2016

  • 22 February

    Trevena’s Pain Drug Receives FDA Breakthrough Therapy Designation

    Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the Company’s lead product candidate, intravenous oliceridine (TRV130), for the management …